chrisvoncsefalvay/vaers-outcomes huggingface dataset:
ANEMIA SECONDARY TO MENSTRUATION; TINGLING OF TONGUE; SORE THROAT; MUSCLE ACHES; FEVER; HEADACHE; This spontaneous report received from a physician concerned a 27 year old female. The patient's height, and weight were not reported. The patient's past medical history included anemia secondary to menstruation. The patient was not pregnant at the time of reporting. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose was not reported, 1 total, administered on 12-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 12-APR-2021 (same day after vaccination), the patient experienced tingling of tongue, sore throat, muscle ache, fever, headache and was hospitalized. On the same day, the patient experienced anemia secondary to menstruation as her hemoglobin was 6.2 (unit not specified) and was transfused. On 13-APR-2021, the patient had a mild headache at night and labile temperatures (her maximum temperature was 101.1 F in 24 hours prior to this report). On 14-APR-2021, the patient symptoms were improved and she had no thrombocytopenia to date. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from tingling of tongue, headache, muscle aches, sore throat, fever, and anemia secondary to menstruation. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0 : 20210429348-covid-19 vaccine ad26.cov2.s- anemia secondary to menstruation. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: MEDICAL HISTORY, UNDERLYING DISEASE 20210429348-JANSSEN COVID-19 VACCINE Ad26.COV2.S-Tingling of tongue, Sore throat. This event(s) are considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). 20210429348-covid-19 vaccine ad26.cov2.s - headache, muscle aches, fever. This event(s) are labeled per  and is therefore considered potentially related.
Information has been received from a certified medical assistant and an unspecified reporter, concerning a 22 year old patient who on 06-JAN-2010 was vaccinated with the first dose and on 03-MAR-2010 with the second dose of GARDASIL (lot # 663558/0819Y). On 14-JUN-2010 the patient went to get the third dose and complained of "having a bump" where the second injection was given. The red bump at injection site has not resolved after 2 months (also reported as "three to four months later the patient still has a red bump"). Follow up information was received from the certified medical assistant who reported that the on 06-JAN-2010 and 03-MAR-2010, the 23 year old female patient (also reported as 22 year old) with no known allergy was vaccinated with the first and second doses of GARDASIL respectively (lot # 663558/0819Y) IM into her left deltoid. There was no known illness at time of vaccination. On 06-JAN-2010, the patient also received a dose of H1N1 IM into her right deltoid (lot # 10132859) and the first dose of FLUZONE IM into her right deltoid (lot #U32711A). The patient called and was concerned about getting the third dose of GARDASIL shot. The patient said that after the second dose was given on 03-MAR-2010, the patient experienced a red bump and was a little tender. At the time of reporting, the outcome was unknown. The patient did not seek medical attention. Additional information has been requested.
reports light-headedness and nausea. VSS. continuous monitoring and approximately 10 minutes later reported that he had difficulty breathing at that time Benadryl 50 mg po was given at 1500. he was then taken to the occupational nurse clinic and laid supine with his legs elevated blood pressure was 140/93 heart rate 97 oxygen concentration 100%. He then reported chills blanket provided for comfort and emotional support given. continuous monitoring and emotional support given. 1515 vital signs were 126 / 82 heart rate 80 oxygen concentration 99% he reports that he is feeling better. He was monitored for an additional 30 minutes in the Med clinic his brother did arrive at 1540 at which time DC instructions were given including calling 911 if symptoms worsen- he gave verbal understanding, all questions answered.
Full body aches, chills, sweats, fatigue and dizziness. Body aches, chills and sweats lasted around 20 hrs. Fatigue and diziness on and off 48rs
enlarged axillary lymph node on L side - vaccination given on L deltoid.  soft, palpable tender to touch, no nodules palpated.  Decreasing in size slowly
I got a headache the Sunday following the vaccine which would have been the 7th of March and still have today (15th).  On the 13th of March, I noticed my left arm  itchy, swollen and red blotches.
Ulcers in mouth, throat, tongue, and on the outside of my vaginal area.
RECEIVED HALF DOSE FOR BOOSTER; OFF LABEL USE; This spontaneous report received from a health care professional concerned a 30 year old female of unspecified race and ethnicity. The patient's weight, height, and medical history were not reported. On an unspecified date, the patient previously received covid-19 vaccine ad26.cov2.s vaccination from an unspecified manufacturer (suspension for injection, route of admin not reported, batch number: unknown expiry: UNKNOWN) dose was not reported, 1 in total, (dose number in series: 1) for prophylactic vaccination and it was unknown whether patient had any adverse events. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1822809 or 211A21A expiry: UNKNOWN) dose was not reported, 1 in total, (dose number in series: 2), administered on 27-NOV-2021 for prophylactic vaccination (RRT: Received half dose for booster, LLT: vaccine underdose, and Off label use). No concomitant medications were reported.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the received half dose for booster and off label use was not reported. This report was non-serious.  This case, from the same reporter is linked to 20211202250, 20211200717, 20211200723, 20211200752, 20211200769, 20211200994, 20211201082, 20211201168, 20211201179, 20211201228, 20211201286, 20211201304, 20211201351, 20211201362, 20211201392, 20211201443, 20211201450, 20211201963, 20211202161, 20211202199, 20211202207, 20211202246, 20211202371, 20211202379 and 20211202193.
Red pinprick rash started on tops of feet and ankles the day after receiving vaccine, spread to thighs, forearms, hands, chest, and upper back another day after that. Rash is intermittently itchy, no weeping or oozing. Injection site red, swollen, and itchy; swelling did not reduce in days following injection, and 8 days later the site is still red, itchy, and inflamed (with a hard bump rather than a soft inflammation).
Redness and swelling to left arm below injection site. Patient reports it started on 2/26/14. Also complains of itching. Red, raised area to left arm. Measures 7 cm long x 14.5 cm wide. Warm to touch. Swelling under left arm - onset 3/3/15. Pt reports tenderness to arm and under arm. Treatment = cool compress as needed, moisturizer.
The patient presented on 6/21/18 with a light red, slightly swollen rash on her left arm that was warm to the touch. The rash started just below the injection site and travelled roughly 6 inches down. The rash also started spreading inwards towards the bicep. The patient stated that the rash was continuing to spread from day 1 (6/19/18) to the time of our encounter on 6/21/18. My initial indication was that she may be experiencing cellulitis and recommended her to follow-up with her primary care physician.
Not feeling well; This is a spontaneous report received from a contactable reporter (Consumer). The reporter is the patient.  A patient (no qualifiers provided) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), administration date 12Apr2021 (Lot number: EP7533) as dose 2, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162B2 (Dose 1, Batch/Lot number: unknown), for covid-19 immunization. The following information was reported: MALAISE (non-serious) with onset Apr2021, outcome "not recovered", described as "Not feeling well".  Additional information: The patient received the second dose of the Pfizer Vaccine last Monday, one week ago on 12Apr and was having some side effects and they have not gone away. Patient was not feeling well still and have some side effect going on.   No follow-up attempts are possible. No further information is expected.
Significant deltoid pain (rating 8 out of 10) beginning 10 hours after injection, lasting 24 hours
Information has been received from a physician concerning an 8 year old male who "three weeks ago," on approximately 09-MAR-2007, was vaccinated with 0.5 mL of varicella virus vaccine live (Oka/Merck). Three days post vaccination, on approximately 12-MAR-2007, the patient developed tics. It is unknown what body parts were affected by the tics. At the time of reporting, the patient was not recovered. No lab diagnostics studies were performed. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
I am post pancreatic cancer and I have a combined PET-CT scan every six months. I was in for my normal scan in December of 2021 and we found a nodule in my lung. We did another scan three months later and have done them every three months since then. The nodule has continued to grow since we found it. We did do a chest x-ray and oncology lab work and I have been sent to another specialist for follow up. We did a biopsy in December 2022 and am still working with specialist on what is occurring.
When given the shot I started to bled down my arm. As the day progressed swelling and redness on the injection site worsened. Today 04/07/21 swelling followed the main vein down my arm to my inner elbow. It's painful at the injection and my inner elbow.
On 9/26/2016 went to clinic for the 3rd shot in the series of hep B. Starting getting shoulder pain around 2:00 pm. Then it proceeded into my back in the shoulder blade area. Tuesday 9/27/2016 my chest was hurting, felt like a pulled muscle. Wednesday 9/28/2016 when I woke up my left wrist and left ankle was all swollen up. Could barely move them but my chest was better. Went to urgent care on 9/30/2016 where the dr on duty told me that he thought he was a reaction to the shot I gotten and just to wait a couple of days till my body absorbed the shot. Woke up on 10/3/2016 with my face swollen especially on the left side. My work sent to clinic where the dr on duty there said he had no clue what it was from and recommended me to go see my dentist. On 9/4/2016 went to my doctor and after looking and feeling my face decided it was a possible reaction to the shot. My glands in my cheek were all swollen. Dr prescribed me a anti-inflammatory to help with the swelling. My left side was more swollen than the right side. The swelling started going down on 10/6/2016 and by 10/10/2016 the swelling was completely gone.
Appetite lost/loss of appetite; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (Appetite lost/loss of appetite) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    There was no reported medical history.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced DECREASED APPETITE (Appetite lost/loss of appetite). At the time of the report, DECREASED APPETITE (Appetite lost/loss of appetite) had not resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Formulation for HUMIRA was given as Solution for injection in pre-filled pen.  The reporter's causality with HUMIRA for the event of decreased appetite was not provided.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Pt diagnosed with Guillain-Barre-symptoms developed on 11/12/09. Pt c/o leg pain, unsteady gait, slurred speech, tremors, falling down, up all night screaming. Referred to ER.  12/08/09, 12/29/09 MR and DC summary for DOS 11/14/09  11/23/09. DX: GBS Pt presented with difficulty walking, unsteady gait with 7-10 days hx. On examination: alert, fluent speech, cranial nerves intact, strength 5/5 in upper extremities, low. Tx: IVIg therapy, Neurontin. Pt improved and discharged home with an OT appointment.  12/22/09 and 12/28/09 MR received for 11/27/09 and 12/03/09 Pt c/o weakness, tremor, difficulty sleeping. Pt to continue Neurontin and started Claritin.
Hypersensitivity to flu vaccine - joints, back and (R) armpit edema/pain malaise, dizziness, headache, elevated blood pressure.
Fever 101 F, 24 hours. Body aches and headache, 48 hours.
pt recv vax; failed to seroconvert;12jan96 presented to MD w/ "full case" of chicken pox;
Vaccine was in thaw state (2 to 8 degree Celsius) from about 20-Dec-2021; Patient received vaccine past its 30 days expiry date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received vaccine past its 30 days expiry date) and PRODUCT STORAGE ERROR (Vaccine was in thaw state (2 to 8 degree Celsius) from about 20-Dec-2021) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Mar-2022 at 11:08 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 13-Mar-2022 at 11:08 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received vaccine past its 30 days expiry date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was in thaw state (2 to 8 degree Celsius) from about 20-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received vaccine past its 30 days expiry date) and PRODUCT STORAGE ERROR (Vaccine was in thaw state (2 to 8 degree Celsius) from about 20-Dec-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported by reporter.  Vaccine was in thaw state (2 to 8 degree Celsius) from about 20-Dec-2021.  No treatment medication was reported by reporter.
Tinnitus from the day of vaccination continuing on through today.   Going on now for 2 weeks.
Fever, Chills, Sweats, Weakness, Muscle ache, Joint ache, loss of appetite, poor sleep, Bad headache.  This was from a Flu Vaccine.
Chills, headache, and fever started approximately 12 hours after shot. Teeth chattered for 3 1/2 hours. Extreme pain in arm and ?Covid arm? : large rash on arm. By 36 hours post shot, fever went up significantly, both arms & hands tingling/numb. Severe aching in neck & lower back. 48 hours post shot, feeling better with just a small headache. 60 hours post shot: SEVERE headache. Cant lift head.
Pt recvd Rubella vax on 25MAR92 & approx 4 wks p/vax pt exp fever, aches, arthritis, arthralgias, SOB, bilateral pleural effusions, & pericarditis; pt hospitalized; fever;
Immediately after administration of vaccines, patient lost consciousness, became pale, and stopped breathing for approximately 45 seconds.  He regained consciousness and full mental capacity within minutes of recovery.
+ AXILLARY SWELLING LEFT SIDE WITH LYMPHADENOPATHY ONLY AT LEFT AXILLARY REGION. ITCHING AT Narrative:
Patient's (mom) caregiver reported patient was experiencing  right arm numbness within 10 to 15 minutes of his 2nd covid-19 immunization.  In addition, pain in the right arm was initially reported.   Over the next few minutes, while discussing the arm pain, patient reported worsening of symptoms  extending to right leg and right side of mouth.  Emergency services (EMT) was called and patient was taken to Emergency Departemnt.
Pregnant and due June 28th, 2021.   Constant Ringing/humming sound in right ear.
On day two after receiving  the vaccine, I experienced body aches.  On day four after receiving the  vaccine, I experienced severe pain and tenderness in right arm, shoulder area.  Sometimes a little pain and numbness extending to the hand.  Today is day six, severe pain and tenderness in the shoulder area of the right arm  still exists along with some numbness in the hand area.
pt recv vax late morning 10AM & father reports 4Pm significant rash covering trunk, on neck, shoulders;no fever c/o flushed feeling;
Fever, chills, body aches, headache and abdominal pain. Took second dose yesterday, I was feeling fine and it all came back.
Patient experienced a rush of heat followed by nausea and dizziness. The patient felt clammy and sweaty. Dizzy spells were cyclical.
This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itches but not a lot), URTICARIA (Could be hives) and VACCINATION SITE SWELLING (Tennis ball sized area below the site of injection on her right upper arm) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination. Concomitant products included GABAPENTIN and MELATONIN for an unknown indication. On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, the patient experienced PRURITUS (Itches but not a lot), URTICARIA (Could be hives) and VACCINATION SITE SWELLING (Tennis ball sized area below the site of injection on her right upper arm). At the time of the report, PRURITUS (Itches but not a lot), URTICARIA (Could be hives) and VACCINATION SITE SWELLING (Tennis ball sized area below the site of injection on her right upper arm) outcome was unknown. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No treatment information was provided.
Fever 100.9, body aches, headache, runny nose, sore throat, fatigue, no taste or smell, cough symptom onset 07/28/2021
Pfizer vaccine bottle was not reconstituted with saline. 0.3ml was given to patient for a total of 6 doses at one time. Patient had very sore arm, headache and felt tired
Temperature 99.2; sinus pressure/headache; sinus pressure/headache; whole body ache; My first and second dose was less than 21 days apart.; This is a spontaneous report from a contactable (patient). A 42-year-old female patient receive second dose of bnt162b2 (lot number: EL1283), via an unspecified route of administration, at arm left, on 21Jan2021 at single dose for covid-19 immunisation. Medical history was none. Not Pregnant at the time of vaccination. No Allergies to medications, food, or other products. No Known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication received within 2 weeks of vaccination included vitamin d nos (VITAMIN D NOS), ascorbic acid (VIT C), fish oil (FISH OIL), chondroitin sulfate sodium, glucosamine (GLUCOSAMINE AND CHONDROITIN). The patient historical vaccine included first dose of bnt162b2 (lot number: EK9231), intramuscular, at Arm Left, on 07Jan2021 09:00 AM (42-year-old) for covid-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient has not been tested for COVID-19. The patient experienced temperature 99.2, sinuspressure/headache, whole body ache. Her first and second dose was less than 21 days apart. The adverse event started from 21Jan2021 09:00 PM. No treatment was received for the adverse event. Seriousness was reported as NO. The outcome of the event was recovering.
nonoliguric acute renal failure scondary to interstitial nephritis which was demonstrated by percutaneous biopsy; No med prior to back pain beginning on 31MAY92;
blood clot in her lungs; shortness of breath; chest pain; exertion when walking; This is a spontaneous report from a contactable consumer, based on information received by Pfizer  (manufacturer control number: (Not provided)), for bnt162b2 (CO-MIRNATY). A 51-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VAC-CINE, formulation: Solution for injection, Batch/lot number was not reported) via an unspecified route of administration on 03Mar2021 (age at vaccination 51years old) as single dose for covid-19 immunisation. Medical history included obesity from an unknown date and unknown if ongoing, malaise from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient experienced blood clot in her lungs on Mar2021, shortness of breath, chest pain on an unspecified, exertion when walking on an unspecified date. The patient had a very large bilateral blood clot in her lungs. She underwent urgent thrombectomy procedure shortly after admission and recovered. Most, but not all, of the clot was successfully re-moved. The doctor told her that she was very lucky to be alive as they usually only see blood clots that big on autopsy. It was imagined they would have performed a SARS-CoV test, but I am not sure of the results. I will try to find out more. Her symptoms were shortness of breath, chest pain, and exertion when walking. reporter was not sure if she is on any cc meds or what anticoagulant therapy she was placed on. If I can find out the name of the treating physician. I will pass that along as well so your company can contact them directly. The patient was scheduled to remain in the hospital for the next 3-4 days. The patient was hospitalized for blood clot in her lungs from unspecified date in Mar2021 and patient was discharged from the hospital on 18Mar2021. The patient underwent lab tests and procedures which included autopsy: blood clots on Mar2021 blood clots that big on, sars-cov-1 test: unknown on Mar2021 and not sure of the results, thrombectomy: blood clots on Mar2021 clot was successfully removed. The clinical outcome of the event blood clot in her lungs was recovered in March2021 and other events was unknown. Therapeutic measures were taken as a result of blood clot in her lungs.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Pt developed numbness in the effected arm right after the injection. Symptoms improved over the course of several minutes and pt reports only minimal numbness in forearm and hand currently. There has been no decrease in motor function. PCP f/u recommended for any continued symptomsl
Initial report was received from a health care professional on 30 March 2012. An 11-year-old female patient had received the following vaccinations on an unknown date: ADACEL, sanofi pasteur Ltd., lot number C3915 (sanofi pasteur Inc. lot number U3979BA), FLUZONE, sanofi pasteur Inc., lot number UH455AD, MENACTRA, sanofi pasteur Inc., lot number U4028AH and VARIVAX, Merck, lot number not reported (sites and routes not reported) and an unspecified amount of time later the patient experienced tingling in feet. The tingling had slightly improved. Illness at the time of vaccination, concomitant medications and past medical history was unknown. The patient's outcome was not recovered. Documents held by sender: None.